On Dec. 28, 2023, the Centers for Medicare and Medicaid Services (CMS) released a final rule that updates Clinical Laboratory Improvement Amendments of 1988 (CLIA) fees and clarifies CLIA regulations.

Palo Alto lab enables faster turnaround times and increased capacity for ultrasensitive, amplicon-based liquid biopsy testing for US customers PALO ALTO, Calif.--(BUSINESS WIRE)--Molecular diagnostics ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellworks Group, Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced that its computational laboratory ...

Ensuring quality and compliance is at the core of every successful clinical laboratory. This webinar brings together CAP expert Daniel and Christie, QA leader from Burning Rock, to explore the ...

Comprehensive pharmacogenetic assay focused on psychiatry and neurology advances precision medicine for the brain. KEARNY, N.J., Nov. 21, 2024 /PRNewswire/ -- NeuroKaire, a pioneering biotechnology ...

CMS has issued a final rule that gives the agency greater discretion in enforcing the Clinical Laboratory Improvement Amendments, according to the Taking Essential Steps for Testing Act of 2012. Under ...

ST. PAUL, Minn., Jan. 21, 2026 /PRNewswire/ -- Zepto Life Technology has announced the launch of the FungiFlex (R) Mold Panel, a plasma-based molecular diagnostic test now available through its ...

The undertaking of research in human participants often includes development of clinical laboratory test results associated with an individual research participant. Depending in part on the specified ...

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory has achieved College of American Pathologists (CAP) ...

Marlborough, Mass.-based Akoya Biosciences was awarded CLIA certification for its Advanced Biopharma Solutions lab, the company said in a Nov. 30 news release. The lab specializes in spatial biology, ...

ALAMEDA, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its ...